Accelerated dTMS Smoking Cessation
Key facts
- Who runs it
- Waypoint Centre for Mental Health Care
- Where
- Canada2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 24 Feb 2026
- Expected to end
- 1 Jan 2028
- Type of study
- Interventional
- Treatments tested
- Bilateral deep accelerated repetitive transcranial magnetic stimulation
- Record updated
- 21 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Aged 18 years or older
- Tobacco use disorder as assessed by DSM-5
- Fagerstrom Test of Nicotine Dependence (FTND) ≥ 4
- Reported motivation to quit within 30 days as assessed using the Contemplation Ladder score of ≥ 7
- Must sign and date the informed consent form
- Stated willingness to comply with all study procedures
- Able to communicate in English
Who cannot take part
- Concomitant use of medication that lowers seizure threshold, such as clozapine
- Concomitant use of more than 2 mg lorazepam (or an equivalent) or any anticonvulsants
- Current or recent history of cerebrovascular disease
- Unstable major psychiatric disorder(s) (i.e. Axis I Disorders) that would prevent participation in the study at PI (or its delegate) discretion
- Serious current or personal history of medical condition/disease (neurological disorders, brain lesions, multiple sclerosis, head trauma, loss of consciousness, hearing loss, etc.) preventing same inclusion as per PI (or its delegate) discretion
- Current, personal history or family history of seizures
- Reported smoking abstinence in the 3 months preceding screening visit
- Current use of other smoking cessation aids
- Contraindication to rTMS
- Pregnancy, trying to become pregnant or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to examine whether a 5-day course of bilateral accelerated deep transcranial magnetic stimulation (aTMS) is a feasible treatment to help adults (18-65) with Tobacco Use Disorder to quit smoking. This study aims to enroll 30-40 participants and will examine treatment tolerability, treatment acceptability, participant retention, and adherence to scheduled treatment sessions.
Read full original descriptionShow less
There are two key objectives and hypotheses:
Objective 1: To evaluate whether a 1-week course of bilateral aTMS (4 sessions per day for 5 days) is feasible and tolerable as a smoking cessation treatment.
Hypothesis 1: Feasibility will be demonstrated by acceptable tolerability, acceptability, retention, and adherence, with a practical target of 30 out of 40 participants completing the treatment.
Objective 2: To explore how aTMS affects smoking outcomes, including:
* Point-prevalence abstinence at end of treatment and at Weeks 3, 5, and 9. * Prolonged/continuous abstinence at Weeks 13 and 26. * Craving, cigarettes per day, and dependence severity. Hypothesis 2: Participants will show improvements on these outcomes from post-treatment through follow-up.
The group in the trial
- Accelerated Repetitive Transcranial Magnetic StimulationTreatment being tested
Bilateral Accelerated Repetitive Transcranial Magnetic Stimulation targeting the insula and prefrontal cortex using H4 coil
Treatment: Bilateral deep accelerated repetitive transcranial magnetic stimulation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Accelerated Deep Transcranial Magnetic Stimulation for Smoking Cessation
- Record updated
- 21 April 2026